Search

The development of moxifloxacin began in 1994 in Germany. The first preclinical data published in 1996 highlighted its excellent activity against a broad range of pathogens. In 1999, moxifloxacin was licensed for use in Europe and the USA for the treatment of respiratory tract infections and, since then, has also been approved for use in pelvic inflammatory disease, complicated skin and skin structure infections, and complicated intra-abdominal infections. This book reviews 10 years of clinical experience with moxifloxacin and provides a valuable reference source to support the use of moxifloxacin in clinical practice.

Analyzing preventive strategies, as well as emerging trends in the bacteriology, pathogenesis, diagnosis, and management of disease, this reference explores factors that lead to the development of severe pneumonia, the most effective treatment methods for the condition, and recent efforts to improve disease outcomes-describing patients at risk for